Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 144 Insider Sale of Securities
  2. 144 Insider Sale of Securities
  3. 4 Planned sale Director sold 1,666 shares at an average $29.84 ($49,709)
  4. 144 Insider Sale of Securities
  5. 4 Open-market sale President and CEO sold 50,000 shares at $31.40 ($1,570,000)
  6. 8-K Event Other events
  7. 144 Insider Sale of Securities
  8. 4 Grant or award Director acquired 4,216 shares (grant or award)
  9. 4 Grant or award Director acquired 4,216 shares (grant or award)
  10. 4 Grant or award Director acquired 4,216 shares (grant or award)
  11. 4 Grant or award Director acquired 4,216 shares (grant or award)
  12. 4 Grant or award Director acquired 4,216 shares (grant or award)
  13. 4 Grant or award Director acquired 4,216 shares (grant or award)
  14. 4 Grant or award Director acquired 4,216 shares (grant or award)
  15. 4 Grant or award Director acquired 4,216 shares (grant or award)
  16. 4 Grant or award Director acquired 4,216 shares (grant or award)
  17. 4 Grant or award Director acquired 4,216 shares (grant or award)
  18. 8-K Event Other events
  19. 8-K Event Shareholder vote results
  20. 4 Open-market sale COFO and Secretary sold 10,000 shares at an average $28.60 ($286,044)

Page 15 of 40 · 789 filings